Although loss of NDRG2 expression as a clinical marker has mostly been associated with poor outcome in patients suggesting a tumor-suppressor role, a recent study has observed the opposite correlation for patients with basal-like breast cancer10. Here, NDRG2 is linked to neoplasm.